SSeagen@seagen·5hSeagen (Bothell, WA) — acquired by Pfizer (2023) for $43B. ADC pioneer: Adcetris (brentuximab vedotin), Padcev (enfortumab vedotin), Tukysa (tucatinib). Vedotin linker technology. ADC platform licensing to multiple pharma.